Active ingredientPimozideCat. No. P-P115-001CAS 2062-78-4Family · Pharmaceutical analytical standards
Pimozide
An antipsychotic of the diphenylbutylpiperidine family developed in Belgium in 1963; it is used for Tourette syndrome and, in Europe, also for some chronic psychoses. This family brings together the active ingredient, pharmacopoeial impurities, labelled standards, nitrosamines and other impurities.
Did you know?In the United States it was approved in 1985 as an 'orphan drug' specifically for Tourette syndrome; it has a very long half-life, about 55 hours in adults.
Go to the active ingredient →Active ingredientPimozideCat. No. P-P115-001CAS 2062-78-4
Pharmacopoeial impurityPimozide EP Impurity DCat. No. P-P115-002CAS 2749415-55-0
Pharmacopoeial impurityPimozide EP Impurity A HClCat. No. P-P115-003CAS 6961-12-2
Pharmacopoeial impurityPimozide EP Impurity CCat. No. P-P115-004CAS 2512213-29-3
Isotopically labelledPimozide-d4Cat. No. P-P115-005CAS 1803193-57-8
NitrosamineN-Nitroso Pimozide Impurity 1Cat. No. P-P115-006
ImpurityPimozide Impurity 1Cat. No. P-P115-007CAS 16148-06-4
ImpurityPimozide Impurity 2Cat. No. P-P115-008CAS 612848-74-5
ImpurityPimozide Impurity BCat. No. P-P115-010
ImpurityPimozide Impurity ECat. No. P-P115-012
ImpurityPimozide OlefinCat. No. P-P115-013No product matches your search.
EDQM standards 3
The official European Pharmacopoeia standards for this family.
Reference substancePimozide CRSEDQM code P1750000Family PimozideImpurityPimozide impurity D CRSEDQM code Y0002394Family PimozideNeed a molecule you cannot find?
Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.